Progesterone Lab Results: Normal Ranges, Cycle Phases, and What Your Number Really Means

Why Progesterone Is the Most Misread Lab in Women's Health

A single progesterone result, stripped of timing context, tells you almost nothing. Clinicians and patients alike see a number like 0.6 ng/mL and panic, or see 8 ng/mL and assume everything is fine, without knowing whether the test was drawn at cycle day 5 or cycle day 21. The error is not the lab; it is the interpretation.

Progesterone is produced primarily by the corpus luteum, the temporary endocrine structure that forms after an egg is released. Ovulation is the switch. Before ovulation, progesterone is nearly undetectable. After a successful ovulatory event, it rises sharply, peaks around seven days post-ovulation, and then collapses if conception does not occur. That collapse triggers menstruation.

This means progesterone is one of the few hormones in medicine where a result of 0.3 ng/mL can be completely normal (follicular phase) or a sign of anovulation (if drawn when ovulation was expected). Cycle timing is not optional information. It is the entire interpretive framework.

Why Women's Physiology Makes This Uniquely Complex

Women's progesterone does not follow a flat reference range the way creatinine or sodium does. It oscillates across a 45-to-50-fold range within a single menstrual cycle. The standard adult female reference interval published by the Endocrine Society spans from <1 ng/mL (follicular) through >25 ng/mL (peak luteal) in reproductive-age women, a span that would be considered catastrophic instability in almost any other analyte.

Add to this the fact that progesterone assays vary between laboratories, between immunoassay platforms, and between liquid chromatography-mass spectrometry (LC-MS/MS) methods. LC-MS/MS is more accurate at low concentrations (below 1 ng/mL), which matters enormously when you are trying to detect anovulation or monitor postmenopausal HRT. Always confirm the units (ng/mL vs nmol/L) and the assay method before interpreting a result. To convert ng/mL to nmol/L, multiply by 3.18.

Normal Progesterone Ranges Across the Menstrual Cycle

The most clinically useful way to organize progesterone reference values is by cycle phase, not by a single population-average range.

Follicular Phase (Cycle Days 1-13, Approximately)

Progesterone is <1 ng/mL and frequently <0.5 ng/mL. This is normal. The ovaries are growing follicles, estrogen is rising, and the corpus luteum does not yet exist. A progesterone drawn in the follicular phase is useful only to establish a low baseline or to detect an abnormal elevation (which can indicate a luteal cyst, adrenal overproduction, or, rarely, an exogenous source).

Periovulatory Phase (Around Cycle Day 14)

Just before ovulation, a small progesterone rise occurs from the dominant follicle, typically reaching 1-3 ng/mL. This pre-ovulatory progesterone rise contributes to cervical mucus changes and primes the endometrium for the post-ovulatory progesterone surge.

Luteal Phase (Cycle Days 15-28, Approximately)

This is the only window in which measuring progesterone is diagnostically meaningful for most questions. The corpus luteum secretes progesterone in pulses, reaching peak serum concentrations roughly 5-9 days after ovulation.

A mid-luteal serum progesterone above 10 ng/mL is the most widely cited threshold for confirming that ovulation occurred. Some reproductive endocrinologists and ASRM-aligned guidelines use 3 ng/mL as the minimum threshold, with values between 3 and 10 ng/mL suggesting ovulation occurred but corpus luteum function may be suboptimal. Values above 20 ng/mL reflect a healthy, strong luteal phase.

The practical rule: if you are checking progesterone to confirm ovulation, the test should be drawn approximately 7 days after a positive LH surge, or on cycle day 21 if cycles are consistently 28 days. Irregular cycles require tracking first.

Luteal Phase Deficiency: What the Evidence Actually Says

Luteal phase deficiency (LPD) is a contested diagnosis. A 2012 ASRM committee opinion noted that no single progesterone threshold reliably defines LPD, partly because corpus luteum secretion is pulsatile and a single draw can miss the peak. Some endocrinologists use three serial progesterone measurements summed to a target of >30 ng/mL across the luteal phase as a more reliable method than one mid-luteal draw. This approach is not universally adopted but reflects the pulsatility problem honestly.

Progesterone Through Every Life Stage

Reproductive Years (Ages 18-40)

In ovulatory cycles, mid-luteal progesterone typically falls between 5 and 25 ng/mL. Cycle-to-cycle variability is normal. A single low result does not equal infertility. What matters is pattern: consistently low mid-luteal progesterone across multiple cycles, especially combined with a short luteal phase (fewer than 11 days from ovulation to menstruation), warrants further evaluation.

Women with PCOS often have anovulatory cycles despite apparent regularity, meaning their mid-luteal progesterone may be <3 ng/mL even when periods arrive on schedule. This is because anovulatory cycles can still shed the uterine lining via estrogen withdrawal. A progesterone draw on cycle day 21 is one of the simplest, cheapest ways to detect occult anovulation in PCOS.

Hormonal acne, perimenstrual mood symptoms, and heavy periods are all associated with low or rapidly declining luteal-phase progesterone. The evidence linking absolute progesterone levels to PMS severity is weaker than often claimed, but the rate of progesterone decline in the late luteal phase appears to be the relevant variable for mood symptoms, not the peak value.

Trying to Conceive

If you are actively trying to conceive, progesterone serves two purposes: confirming ovulation occurred, and (in early pregnancy) supporting implantation and the developing pregnancy before the placenta takes over.

A single mid-luteal serum progesterone <10 ng/mL in a woman trying to conceive warrants discussion about luteal support, though the evidence for supplementation in spontaneous cycles without IVF is less clear than in assisted reproduction. Your clinician may recommend vaginal progesterone (Crinone, Prometrium vaginally) or oral micronized progesterone as empiric luteal support while further evaluation proceeds.

Perimenopause: The Most Variable Stage

Perimenopause is where progesterone interpretation gets genuinely difficult. Cycles may appear regular for years while the luteal phase quietly shortens and progesterone production becomes erratic. A woman in early perimenopause may have a luteal progesterone of 18 ng/mL in one cycle and 2 ng/mL in the next, with no change in cycle length that would tip her off.

The Study of Women's Health Across the Nation (SWAN) documented that reproductive hormone variability, including progesterone, increases substantially before menstrual irregularity begins. This means that a perimenopausal woman with a low mid-luteal progesterone on one draw may not be anovulatory every cycle. Repeat testing over 2-3 cycles gives a more accurate picture.

Perimenopausal progesterone decline is clinically relevant because progesterone is the primary protection against estrogen-driven endometrial proliferation. Women who experience estrogen dominance symptoms (heavy irregular bleeding, breast tenderness, bloating) in perimenopause often have adequate estrogen but insufficient luteal-phase progesterone to oppose it.

Postmenopause

After menopause, ovarian progesterone production essentially stops. Postmenopausal serum progesterone is typically <0.2 ng/mL in women not on HRT. Any measurable progesterone in a postmenopausal woman not taking exogenous progesterone warrants investigation for an adrenal source or exogenous exposure.

Women on menopausal hormone therapy containing micronized progesterone (Prometrium, Utrogestan) will have detectable progesterone levels that vary by dose, timing, and route. Monitoring is discussed in the HRT section below.

Progesterone in Pregnancy and Lactation

This section is required reading if you are pregnant, trying to conceive, or using progesterone supplementation.

First Trimester

In early pregnancy, progesterone is produced by the corpus luteum until the luteal-placental shift occurs at approximately 8-10 weeks, after which the placenta takes over. A first-trimester progesterone <5 ng/mL is strongly associated with pregnancy loss, while values above 20 ng/mL in the first trimester are reassuring for ongoing intrauterine pregnancy. A progesterone of 10-20 ng/mL requires clinical correlation with ultrasound and hCG trend.

Reference ranges for pregnancy:

• First trimester: 11-44 ng/mL
• Second trimester: 19.5-82.5 ng/mL
• Third trimester: 65-290 ng/mL

Progesterone Supplementation in Pregnancy: Safety Data

Vaginal micronized progesterone is used to support early pregnancy in assisted reproduction and in women with a history of recurrent pregnancy loss. It is FDA pregnancy category B (animal data reassuring, human data limited but generally supportive). A 2020 Cochrane review found vaginal progesterone may reduce miscarriage risk in women with early pregnancy bleeding and a viable embryo on ultrasound.

Progesterone is also used to reduce preterm birth risk in women with a short cervix or prior preterm birth. The ACOG practice bulletin on preterm labor endorses vaginal progesterone for women with a singleton pregnancy and cervical length <20 mm before 24 weeks.

Oral micronized progesterone crosses into breast milk. Serum concentrations in nursing infants of mothers taking oral progesterone are generally below the limit of quantification, but data are limited. Vaginal progesterone has lower systemic absorption and lower transfer to milk, making it the preferred route when progesterone is needed postpartum or during lactation. Discuss with your clinician before starting any progesterone during breastfeeding.

Synthetic progestins (medroxyprogesterone acetate, norethindrone, levonorgestrel) are not the same as micronized progesterone. Their pharmacology, receptor binding, side-effect profiles, and breast milk transfer differ substantially. This article addresses bioidentical micronized progesterone unless otherwise stated.

Contraception Note

Progesterone testing is used diagnostically, not as contraception. If you are using progesterone-containing contraception (Mirena IUD, Nexplanon, progestin-only pills), your serum progesterone will reflect the synthetic progestin to varying degrees depending on the assay. Most standard immunoassays do not cross-react equally with all progestins, so serum progesterone measured on OCP or IUD may not reflect the contraceptive's progestin exposure accurately.

Progesterone in HRT: Monitoring and Target Levels

For postmenopausal women using combined estrogen-progesterone HRT, monitoring serum progesterone is not universally required but is used in specific situations: to confirm absorption of oral micronized progesterone, to adjust dose in women with breakthrough bleeding, and in compounded HRT where bioavailability is less predictable.

The Menopause Society (formerly NAMS) 2022 position statement does not specify a target serum progesterone level for HRT monitoring, in part because endometrial protection with oral micronized progesterone at standard doses (100-200 mg/day) is established without relying on serum levels as a surrogate.

Where serum monitoring becomes more relevant is with compounded vaginal or topical progesterone. Transdermal progesterone cream produces inconsistent serum levels and may not reliably protect the endometrium even when salivary or serum progesterone appears adequate. This is a known limitation that many compounding advocates understate.

A WomanRx clinical framework for interpreting progesterone on HRT:

| HRT Route | Expected Serum Progesterone | Endometrial Protection Confidence | |---|---|---| | Oral micronized 100 mg nightly | 2-10 ng/mL (trough) | Well-established | | Oral micronized 200 mg nightly | 5-20 ng/mL (trough) | Well-established | | Vaginal micronized 100 mg | <1 ng/mL (serum low; local uterine effect) | Supported by trial data | | Transdermal progesterone cream | Variable, often <1 ng/mL | Limited; not FDA-approved for this indication | | Compounded vaginal suppository | Variable by formulation | Requires compounding pharmacy documentation |

The paradox of vaginal progesterone is the "first uterine pass" effect: high local endometrial concentrations can coexist with low serum levels, which means serum monitoring alone can mislead.

Conditions That Directly Affect Progesterone Levels

PCOS

PCOS is the most common cause of anovulatory infertility and produces consistently low mid-luteal progesterone in women who are not ovulating. Approximately 70-80% of women with PCOS have irregular or absent ovulation. A mid-luteal progesterone <3 ng/mL in a woman with suspected PCOS is strong evidence of anovulation and should prompt evaluation with ultrasound, LH, FSH, and androgen levels.

Ovulation induction with letrozole (the ASRM-preferred first-line agent) or clomiphene typically produces higher mid-luteal progesterone values than spontaneous anovulatory cycles, but values can still be lower than in natural ovulatory cycles. The NEJM PPCOSII trial comparing letrozole to clomiphene found higher ovulation and live birth rates with letrozole; luteal progesterone was used as an ovulation marker in that trial.

Hypothyroidism

Thyroid dysfunction impairs the hypothalamic-pituitary-ovarian axis and can reduce luteal-phase progesterone. Subclinical hypothyroidism is associated with luteal phase deficiency and early pregnancy loss. TSH above 2.5 mIU/L in women trying to conceive is considered a treatment threshold by many reproductive endocrinologists, partly because thyroid optimization may improve luteal progesterone adequacy. Always check TSH alongside progesterone in women with infertility or recurrent pregnancy loss.

Hyperprolactinemia

Elevated prolactin suppresses GnRH pulsatility, reduces LH amplitude, and directly impairs corpus luteum function. Women with hyperprolactinemia may have luteal phase progesterone values well below the ovulatory threshold even in cycles where ovulation technically occurred. Treating the prolactin excess with cabergoline or bromocriptine typically restores normal luteal progesterone.

Endometriosis

Women with endometriosis may demonstrate progesterone resistance at the tissue level, meaning endometrial cells do not respond normally to circulating progesterone even when serum levels appear adequate. This is an active area of research, and it helps explain why some women with endometriosis have implantation failure or early pregnancy loss despite ostensibly normal luteal progesterone numbers. Serum progesterone does not tell you about endometrial progesterone receptor expression.

Who Should Get a Progesterone Test, and When

Progesterone testing is appropriate in the following situations, framed by life stage and clinical question:

Reproductive years, trying to conceive: Draw on cycle day 21 (or 7 days post-LH surge) to confirm ovulation. Repeat for 2-3 cycles if anovulation is suspected.

Reproductive years, irregular periods or PCOS: Mid-luteal progesterone to detect occult anovulation. Pair with TSH, prolactin, free androgen index.

Perimenopause: Mid-luteal progesterone may detect early anovulation and help explain heavy or irregular bleeding. A single low value is less meaningful than a pattern across cycles.

Early pregnancy: Serum progesterone at 4-8 weeks to assess corpus luteum adequacy, particularly with pain, bleeding, or history of recurrent loss. Pair with serial hCG.

HRT monitoring: Not required routinely for FDA-approved oral micronized progesterone at labeled doses. Useful for compounded formulations, unexplained breakthrough bleeding, or concern about absorption.

Postmenopause, not on HRT: Any detectable progesterone (>0.5 ng/mL) without a clear exogenous source warrants adrenal evaluation.

Who Does Not Need Routine Progesterone Testing

Progesterone testing is not indicated for women on combined oral contraceptives (the pill suppresses ovulation, so the result will be low by design and tells you nothing about natural cycle function). Women in the follicular phase with no specific clinical question will get a low number that is uninformative. Screening healthy, asymptomatic reproductive-age women without fertility concerns or cycle irregularity is not supported by current guidelines.

Interpreting a Low Progesterone Result: A Practical Framework

Before concluding that low progesterone means a problem, confirm these four variables:

1. Cycle day and timing of draw. Day 21 in a 28-day cycle is appropriate. Day 21 in a 35-day cycle is mid-follicular. Wrong timing produces a false low.

2. Was ovulation confirmed? A positive LH surge 7 days before the draw makes interpretation more reliable than using cycle day alone.

3. Assay method. LC-MS/MS at low concentrations is more reliable than immunoassay. Ask the lab which method was used.

4. Clinical context. A progesterone of 4 ng/mL in a woman with a 26-day cycle, confirmed ovulation, no fertility concerns, and regular periods is very different from the same number in a woman with infertility and a history of early miscarriage.

The honest clinical bottom line: if your mid-luteal progesterone is below 10 ng/mL and you are trying to conceive, that result is worth a conversation with a reproductive endocrinologist or a WHNP with fertility experience. It does not automatically mean you cannot conceive, and it does not mean you need progesterone supplementation without further evaluation.

Evidence Gaps: What We Do Not Know Yet

Women have been under-represented in endocrine and reproductive trials for decades. Several specific gaps are worth naming honestly.

The optimal mid-luteal progesterone threshold for predicting implantation success in natural cycles is not established. The 10 ng/mL cutoff is based on studies from the 1970s-1990s with immunoassay methods that are less accurate than today's LC-MS/MS. It remains the most widely cited threshold despite these methodological limitations.

Progesterone's effects on cardiovascular risk, bone density, and cognitive function in postmenopausal women depend heavily on whether the progesterone is bioidentical micronized progesterone or a synthetic progestin. Most large HRT trials (WHI, HERS) used medroxyprogesterone acetate, not micronized progesterone. The KEEPS trial compared conjugated equine estrogen plus micronized progesterone versus transdermal estradiol plus micronized progesterone in early postmenopausal women and found neither regimen worsened carotid intima-media thickness over 4 years, but the trial was not powered for cardiovascular events.

Salivary progesterone testing, widely marketed to consumers, does not reliably reflect serum or tissue progesterone concentrations. A direct comparison study found poor correlation between salivary and serum progesterone, particularly at the low concentrations relevant in postmenopause and early follicular phase.

If your clinician uses salivary testing to dose your HRT, ask them to justify the evidence basis. Serum progesterone (ideally by LC-MS/MS) remains the standard.